Multiple Myeloma Clinical Trial

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Summary

The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Relapsed or Refractory Multiple Myeloma
≥ 18 years old
Able to provide consent for participation
ECOG status 0-2

Lab values:

ANC ≥ 1,000/µL
WBC count ≥ 2.0/µL
Hemoglobin ≥ 8.0 g/dL
Platelet count ≥ 50,000/µL
AST and ALT ≤ 2 x ULN
Total Bilirubin ≤ 2 x ULN
Creatinine ≤ 2.0 mg/dL

and

Not pregnant or lactating

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

25

Study ID:

NCT00096837

Recruitment Status:

Completed

Sponsor:

Pharmacyclics LLC.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Robert H. Lurie Comprehensive Cancer Center
Chicago Illinois, 60611, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

25

Study ID:

NCT00096837

Recruitment Status:

Completed

Sponsor:


Pharmacyclics LLC.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider